Study drug for advanced ovarian and other solid cancers
Treatments studied
Part of Cancer, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (metastatic) or non-surgically removable cancer, such as specific ovarian, endometrial, lung, breast, mesothelioma, or cervical cancers (depending on the part/cohort).
- Your cancer has measurable tumors on scans (doctors must be able to measure them at the start).
- You have already tried prior treatment and your cancer has progressed after the most recent treatment (timing rules differ by cancer type/cohort).
- For the ovarian cancer groups: your tumor must be the right type (high-grade serous or certain fallopian tube/primary peritoneal cancers) and not several other subtypes (like low-grade, mucinous, clear cell, or neuroendocrine).
- You likely need prior platinum-based chemotherapy, and for some groups you must be “platinum-resistant” or “platinum-sensitive” based on how fast the cancer returned.
- You cannot have certain lung inflammation history (interstitial lung disease/pneumonitis needing steroids recently or currently), and you must not have had a specific prior drug type (topoisomerase 1 inhibitor-based antibody drug conjugate).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Hear when a new High Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.